Evidence map›Paper›PMID 31616158›Full record

ArticleOncoTargets and therapy2019

Chinese perspectives on clinical efficacy and safety of alectinib in patients with

Hui Yu, Si Sun, Xingjiang Hu, Jinjing Xia, Jialei Wang, Haiquan Chen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in OncoTargets and therapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Hui YuDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.
Si SunDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.
Xingjiang HuZhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang, People's Republic of China.
Jinjing XiaDepartment of Medical Science Oncology, Shanghai Roche Pharmaceuticals Ltd., Shanghai, People's Republic of China.
Jialei WangDepartment of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.
Haiquan ChenDepartment of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.
Fudan University Shanghai Cancer Center · CNFirst Affiliated Hospital Zhejiang University · CNRoche (China) · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The incidence of lung cancer is increasing in China, in contrast to trends in Western countries, due to the increasing numbers of smokers and high levels of air pollution. Non-small-cell lung cancer (NSCLC) is the most common form of lung cancer, accounting for approximately 85% of lung cancers. Better understanding of the pathogenesis of NSCLC has led to the identification of multiple genetic mutations and chromosomal translocations such as those in the anaplastic lymphoma kinase (

Indexed as

alectinibanaplastic lymphoma kinaseNSCLCtyrosine kinase inhibitor

Identifiers

PMID31616158
PMCPMC6699152
OpenAlexW2968328776

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.